CN115975876A - 一种预防雏鹅痛风的益生菌及其应用 - Google Patents
一种预防雏鹅痛风的益生菌及其应用 Download PDFInfo
- Publication number
- CN115975876A CN115975876A CN202211522442.3A CN202211522442A CN115975876A CN 115975876 A CN115975876 A CN 115975876A CN 202211522442 A CN202211522442 A CN 202211522442A CN 115975876 A CN115975876 A CN 115975876A
- Authority
- CN
- China
- Prior art keywords
- gout
- probiotic
- group
- test
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 19
- 239000006041 probiotic Substances 0.000 title claims abstract description 12
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 12
- 230000000529 probiotic effect Effects 0.000 title abstract description 7
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002477 vacuolizing effect Effects 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于益生菌功能技术领域。本发明公开了一种预防雏鹅痛风的益生菌，该菌已于2022年5月12日保藏于中国微生物菌种保藏中心，地址为北京市阐扬去北辰西路1号院3号，保藏编号CGMCCNO.24882，分类命名副干酪乳杆菌Lactobac i l l us paracase i.本发明解决了预防雏鹅痛风相关问题。
Description
技术领域
本发明属于一种预防痛风的饲料添加剂，具体涉及一种预防痛风的益生菌的分离与功能鉴定。
背景技术
痛风是由于动物机体内长时间的嘌呤代谢和尿酸排泄异常而引起的一种营养代谢病，导致血液中的尿酸水平升高，尿酸盐在关节表面广泛沉积。痛风在鹅的饲养过程中较为常见，雏鹅患病死亡率高达50％，现在存在的有关于鹅痛风的病症基本都是以治疗为主，养殖者都是在鹅出现痛风的状况后才采取相应的治疗手段，且由于饲养条件的要求，在治疗的同时还在继续饲喂致病的高蛋白饲粮，这就导致很难达到对痛风的根治。
发明内容
本发明公开了一种预防痛风的益生菌，该菌已于2022年5月12日保藏于中国微生物菌种保藏中心，地址为北京市朝阳区北辰西路1号院3号，保藏编号CGMCC NO.24882，分类命名副干酪乳杆菌Lactobaci l l us paracasei.由于鹅的痛风是与在现在的养殖业中饲喂蛋白量过高，雏鹅不能依靠自身的代谢作用将其进行较好的代谢处理。本产品则是以益生菌的调节作用为出发点，通过益生菌在肠道菌群内的调节作用，促进肠道对嘌呤的吸收，减少尿酸的沉积，进而阻断痛风的发生。同时，由于肠道菌群的调节作用，可以在饲喂高蛋白日粮的同时进行处理，即保证了生产的需要，也解决了患病的问题。
本发明技术方案如下：1样品的采集与处理
出发前将所需的耗材准备齐全，取粪盒，镊子和手套。在泡沫箱中放入冰袋，防止采集后的样品细菌继续生长。以痛风恢复后的健康雏鹅为采样对象，用取粪盒扣取其棕色带有绿色纤维且成型的粪便，放入泡沫箱中带回实验室。
2细菌的分离
称取采回的雏鹅粪便1g，加入9ml生理盐水放入漩涡震荡仪中震荡混匀，将混匀后的粪液进行十倍稀释，取稀释液(10-6，10-7，10-8)的稀释液50μL置于到配好的NA琼脂培养基中，用涂布棒涂抹均匀，放入37℃恒温箱中培养24h。用接种环挑取培养基中的单一菌落进行划线，再次放入培养箱中培养，重复3-4次,直到纯化为单一菌落。
3细菌的筛选
通过革兰氏染色对所获得菌株进行形态上的初步筛选，取干净玻片，用接种环取一环无菌水于玻片上，而后挑取少量细菌，涂匀，待干燥后，固定。革兰氏染色：先用草酸铵结晶紫染液染色1mi n，用水冲洗，接着滴加卢氏碘液覆盖1mi n，用水冲洗，然后滴加95％乙醇至乙醇液不呈现紫色时停止约0.5mi n，最后用蕃红染液复染1mi n，水洗。油镜镜检(16×100)，选取革兰氏染色为阳性、形态为杆状或球状的菌株做后备菌株留用。
再通过生化特性试验筛选出产酸、产蛋白酶和淀粉酶的菌。
(1)产酸试验：将通过MRS培养基和革兰氏染色筛选出的细菌菌液按2％接种量接到LB培养基中，每隔2h测定一次培养液的pH值。
(2)产淀粉酶可检测试验：将各株菌点滴到淀粉培养基中，37℃恒温培养24h后滴加碘液，碘液范围要覆盖整个菌落，观察菌落周围有无透明圈。
(3)产蛋白酶试验：将各株菌接到酪蛋白培养基中，37℃恒温培养24h后，滴加酸性汞试剂，观察有无分解透明圈。
4.细菌的鉴定
利用天根生化有限公司的细菌基因提取试剂盒提取DNA，再利用通用引物343F(5′-TAC GGR AGG CAG CAG-3′)和798R(5′-AGG GTA TCT AAT CCT-3′)进行PCR扩增。反应体系25μL：2×premi xTaq12.5μL、上下游引物各1μL、模板DNA2μL、ddH2O8.5μL。PCR反应条件：94℃预变性5mi n；94℃变性30s、64℃退火30s、72℃延伸30s，共30个循环；72℃终延伸10mi n，4℃保存。将得到的PCR产物进行1％琼脂糖凝胶电泳试验测定DNA的大小以及浓度，若获得的信息在预期范围内，将剩余的PCR扩增产物送至上海生工公司进行16S rDNA测序。最后获得的DNA部分序列与NCB I基因库中进行比对，用MEGAⅪ进行发育树的构建，用MegAl i gn进行同源性比较。
本发明有益效果为：利用副干酪乳酸菌RV-M192在产肠道菌群内的调节作用，促进肠道对嘌呤的吸收，减少尿酸的沉积，进而达到预防痛风的作用。
附图说明
图1肾脏组织切片(200x)
具体实施例
益生菌效果验证实验
1.微生物制剂的制作
本试验采用冻干的方法制作益生菌制剂，将筛选鉴定后的细菌接种到200mL LB液体培养基中培养24h，扩培后的菌液与保护剂按1:1比例混合均匀后倒入灭菌的培养皿中，菌液厚度约为培养皿的1/3，放入-80℃预冻5h以上。预冻后用保鲜膜包裹培养皿，在上方用牙签扎孔，均匀密集分布，将处理好的培养皿放入冻干机中制成冻干粉菌制剂。收集冻干菌制剂称量计数后4℃保存。保存时间为两周，步骤计算细菌存活率。对冻干粉制剂进行复水，将复水得到的悬液用无菌生理盐水进行倍比稀释，吸取0.1mL合适浓度均匀涂布于固体培养基中，置于37℃培养，进行菌落计数，最后计算存活率，保证试验周期内冻干粉制剂中有效活菌量。
平板计数公式为：活菌量＝(菌落数/0.1mL)×稀释倍数×100％。
2.模型建立及分组饲喂
选用1日龄的雏鹅作为试验动物，24％蛋白作为痛风模型建立的最佳含量。试验分为5个组，分组1为痛风对照组，2-4为副干酪乳酸菌试验组.
试验雏鹅饲喂统一的24％蛋白含量日粮，每组六只雏鹅，试验1组为对照组灌服于试验组相同剂量的生理盐水，试验2-4组分别灌服1mL副干酪乳酸菌制剂(浓度分别为3x107CFU/mL，3x108CFU/mL，3x109CFU/mL)。雏鹅每天自由采食饮水。
实验用菌剂都是新鲜配制，每天准备好不同的菌液各1管，注意观察鹅的健康、存活等情况，并且做好记录。
3.血液生化指标检测
最后一天灌服菌液2h后，各组雏鹅颈静脉采血，每组采血时间不超过5分钟。在室温的条件下，血液凝固l h后，3500r/mi n离心l0mi n取血清，-20℃保存。用全自动生化分析仪检测血尿酸、尿素氮和肌酐水平，用试剂盒检测黄嘌呤氧化酶XOD含量。
4.HE染色检测肾脏损伤情况
动物处死之后，摘取一侧肾脏生理盐水冲洗血水和粪，4％对聚甲醛固定，石蜡包埋。全部石蜡标本均连续切片，石蜡切片二甲苯脱蜡，经各级乙醇至水洗，苏木素染色，自来水冲洗，盐酸乙醇酸化，水洗，伊红染色，常规脱水，透明中性树脂封片，电镜下扫描。
5.血液指标
表1
由表1可以看出，连续饲喂14d 24％蛋白饲料进行造模后，血液中尿素氮BUN、肌酐CRE、尿酸UA水平和黄嘌呤氧化酶XOD含量有明显的变化，与对照组相比，灌服副干酪乳杆菌RV-M192菌液，中剂量组和高剂量组使尿素氮分别降低10.8％和6.0％，差异显著水平分别为P<0.01和P<0.05；中、高剂量组使肌酐含量降低60％和28.7％，差异显著性水平均为P<0.01；低、中、高剂量组使尿酸水平降低6.4％、16.0％、10.8％，低剂量组差异显著性为P<0.05，中、高剂量组差异显著性为P<0.01；中剂量组使黄嘌呤氧化酶降低8.5％，P<0.01。
6HE染色
连续14d饲喂24％粗蛋白日粮并灌服副干酪乳杆菌RV-M192的益生菌制剂后对雏鹅肾脏的影响结果如图1所示。结果显示，模型组与空白相比，肾小管扩张、结构消失、有明显的空泡化，再次说明试验造模成功。另外，与模型组相比，灌服副干酪乳杆菌RV-M192，中剂量组肾小管上皮空泡化减少，甚至接近于空白组，低剂量组还有明显的空泡化，高剂量组有大量炎性细胞浸润。
Claims (2)
1.一种预防雏鹅痛风的益生菌，其特征为：保藏编号CGMCC NO.24882，分类命名副干酪乳杆菌，拉丁文学名为Lactobacillus paracasei。
2.如权利要求1所述的一种预防雏鹅痛风的益生菌在预防雏鹅痛风领域的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211522442.3A CN115975876B (zh) | 2022-11-30 | 2022-11-30 | 一种预防雏鹅痛风的益生菌及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211522442.3A CN115975876B (zh) | 2022-11-30 | 2022-11-30 | 一种预防雏鹅痛风的益生菌及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115975876A true CN115975876A (zh) | 2023-04-18 |
| CN115975876B CN115975876B (zh) | 2024-04-19 |
Family
ID=85961469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211522442.3A Active CN115975876B (zh) | 2022-11-30 | 2022-11-30 | 一种预防雏鹅痛风的益生菌及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115975876B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014168A1 (en) * | 2007-11-29 | 2011-01-20 | Meiji Dairies Corporation | Lactic acid bacteria having action of lowering blood uric acid level |
| CN102448477A (zh) * | 2009-03-25 | 2012-05-09 | 科·汉森有限公司 | 益生菌在调节体重中的用途 |
| WO2020006663A1 (zh) * | 2018-07-02 | 2020-01-09 | 葡萄王生技股份有限公司 | 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物 |
| CN112694989A (zh) * | 2020-12-21 | 2021-04-23 | 中国海洋大学 | 一株副干酪乳杆菌x11及其组合物便秘复合制剂及乳制品 |
| CN112899190A (zh) * | 2021-02-02 | 2021-06-04 | 生合生物科技（扬州）有限公司 | 对痛风具有预防和/或改善功能的副干酪乳杆菌lpc48及其用途 |
| CN113999805A (zh) * | 2021-12-06 | 2022-02-01 | 四川高福记生物科技有限公司 | 一种防治高尿酸血症的发酵乳杆菌及其组合物与应用 |
| CN114836336A (zh) * | 2021-12-10 | 2022-08-02 | 丁庆 | 一种乳杆菌及其应用 |
-
2022
- 2022-11-30 CN CN202211522442.3A patent/CN115975876B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110014168A1 (en) * | 2007-11-29 | 2011-01-20 | Meiji Dairies Corporation | Lactic acid bacteria having action of lowering blood uric acid level |
| CN102448477A (zh) * | 2009-03-25 | 2012-05-09 | 科·汉森有限公司 | 益生菌在调节体重中的用途 |
| WO2020006663A1 (zh) * | 2018-07-02 | 2020-01-09 | 葡萄王生技股份有限公司 | 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物 |
| CN112694989A (zh) * | 2020-12-21 | 2021-04-23 | 中国海洋大学 | 一株副干酪乳杆菌x11及其组合物便秘复合制剂及乳制品 |
| CN112899190A (zh) * | 2021-02-02 | 2021-06-04 | 生合生物科技（扬州）有限公司 | 对痛风具有预防和/或改善功能的副干酪乳杆菌lpc48及其用途 |
| CN113999805A (zh) * | 2021-12-06 | 2022-02-01 | 四川高福记生物科技有限公司 | 一种防治高尿酸血症的发酵乳杆菌及其组合物与应用 |
| CN114836336A (zh) * | 2021-12-10 | 2022-08-02 | 丁庆 | 一种乳杆菌及其应用 |
Non-Patent Citations (4)
| Title |
|---|
| ABOLFAZL DEHKOHNEH等人: "Effects of probiotic Lactobacillus paracasei TD3 on moderation of cholesterol biosynthesis pathway in rats", IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 30 September 2019 (2019-09-30), pages 1004 - 1009 * |
| JIAYUAN CAO 等人: "Lactobacillus paracasei X11 Ameliorates Hyperuricemia and Modulates Gut Microbiota in Mice", FRONTIERS IN IMMUNOLOGY, 6 July 2022 (2022-07-06), pages 1 - 12 * |
| YOUJIN LEE等人: "Potential Probiotic Lacticaseibacillus paracasei MJM60396 Prevents Hyperuricemia in a Multiple Way by Absorbing Purine, Suppressing Xanthine Oxidase and Regulating Urate Excretion in Mice", MICROORGANISMS, 20 April 2022 (2022-04-20), pages 1 - 20 * |
| 刘慧敏: "乳酸菌嘌呤降解菌株的筛选、基因组特征及其应用研究", CNKI优秀硕士学位论文全文库, 15 August 2021 (2021-08-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115975876B (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103421704A (zh) | 一株淡水鱼发酵制品用的植物乳杆菌及应用 | |
| CN108060104A (zh) | 一种植物乳杆菌及其应用、筛选检定方法 | |
| CN113604404B (zh) | 一种凝结芽孢杆菌ysf17及其用途 | |
| CN105820987A (zh) | 一种地衣芽孢杆菌菌株及微生态制剂 | |
| CN110184214A (zh) | 一种开菲尔乳杆菌及其菌制剂 | |
| CN110028560B (zh) | 一种凝结芽孢杆菌产的细菌素及其应用 | |
| CN117904007B (zh) | 枯草芽孢杆菌菌株sklan202311d及其应用 | |
| CN113502243B (zh) | 一株高产乳酸的植物乳杆菌gbw-lp001及其替抗菌剂和应用 | |
| CN108179122A (zh) | 一种高粘附益生性屎肠球菌及其应用 | |
| CN108060102B (zh) | 一种食窦魏斯氏菌及其应用、筛选检定方法 | |
| CN108060103B (zh) | 一种戊糖片球菌及其应用、筛选检定方法 | |
| CN112625946B (zh) | 枯草芽孢杆菌、微生态制剂、饲料及其在提高种母鸡生产性能和蛋壳质量中的应用 | |
| CN107828703A (zh) | 空间罗伊氏乳杆菌Fullarton‑9‑35及应用 | |
| CN115975876A (zh) | 一种预防雏鹅痛风的益生菌及其应用 | |
| CN114181867B (zh) | 一株植物乳杆菌及其产品和应用 | |
| CN116536195A (zh) | 克劳氏盐碱芽孢杆菌及其在制备有机微生物菌肥中的应用 | |
| CN116606777A (zh) | 一种植物乳杆菌菌株及其饲料添加剂与饲料 | |
| CN107586748B (zh) | 一种中华单孢菌及其应用 | |
| CN114480206B (zh) | 一种耐高温粪肠球菌及其制备方法与应用 | |
| CN114854629A (zh) | 一株植物乳杆菌c-37及其在发酵玉米胚芽粕中的应用 | |
| CN111154677B (zh) | 嗜酸乳杆菌及其应用 | |
| CN109161501A (zh) | 一种饲用地衣芽孢杆菌及其应用 | |
| CN109971667A (zh) | 一株猪源植物乳杆菌及应用 | |
| CN109364102A (zh) | 植物乳杆菌cqpc03在制备预防糖尿病的食品或药品中的应用 | |
| CN115895941B (zh) | 一株鼠李糖乳杆菌及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |